Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company founded on September 28, 2000, and listed on the ChiNext board of the Shenzhen Stock Exchange in 2011. The company specializes in the research, production, and sales of heparin series products, establishing itself as one of the few leading enterprises in China with a complete heparin industrial chain. Changshan Pharma is recognized as a key high-tech enterprise under the China Torch Program and has received various honors for its innovative contributions. The main product offerings of Changshan Pharma include Heparin Sodium API, Enoxaparin Sodium API, Dalteparin Sodium API, Low Molecular Weight Heparin Calcium API, and their respective injections. The Low Molecular Weight Heparin Calcium Injection is noted for its superior quality compared to national standards and is a core product for the company. Changshan Pharma's products have received multiple international certifications and are sold in various countries, including the United States, Germany, and Japan. The company aims to expand its product lines to include anti-diabetes and oncology drugs while enhancing its research capabilities and exploring new markets.

Changshan Pharma is one of the few leading enterprises in China that has a complete heparin industrial chain and can conduct the research, production and sales of heparin API as well as injections. The main products of Changshan Pharma include Heparin Sodium API, Enoxaparin sodium API, Dalteparin Sodium API, Low Molecular Weight Heparin Calcium API, Heparin Sodium Injection, Dalteparin Sodium Injection and Low Molecular Weight Heparin Calcium Injection. Among them, Low Molecular Weight Heparin Calcium Injection produced by Changshan Pharma has a much higher standard than that set by the national standard, and its effect is good. The product is widely recognized by the market and is the core product of Changshan Pharma. Many products have got the EDQM CEP certification, Japanese PMDA certification, German GMP certification, American FDA certification and so on. At present, the products have been sold to many countries such as the American, Germany, Italy, South Korea, Russia, India, Iran, Japan and many other countries. In the future, Changshan Pharma will carry out the strategy with the heparin series as core and the anti-diabetes drugs as well as oncology drugs as two wings, and actively explore overseas markets and promote the export of preparations. The company will strengthen the research and production of silaenafil and hyaluronic acid, develop diversification and enter the new field of medical services. At the same time, the company will speed up the mergers and acquisitions of pharmacy and medical treatment, explore the new growth point the company development, continue to expand the scale of enterprises, enhance core competitiveness and ability to resist risks, and make the company bigger and stronger as soon as possible. The company will improve its R & D capability, enlarge is business scope, promote its development as well as efficiency.